-
Therapeutics and Clinical Risk Management
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia
Review
(1952) Views (2166) Full article downloads
Authors: Ayman A Hussein, Stephen J Nicholls
Published Date April 2010
Volume 2010:6 Pages 183 - 190
DOI: http://dx.doi.org/10.2147/TCRM.S7306
Ayman A Hussein, Stephen J Nicholls
Cardiovascular Medicine Department, Cleveland Clinic Foundation, Cleveland, OH, USA
Abstract: Niacin is a B-complex vitamin which has been used for decades for the management of mixed dyslipidemias and primary hypercholesterolemia. It decreases the risk of cardiovascular events either when used as a monotherapy or in combination with other lipid lowering medications. However, a major limitation to its use is niacin-induced flushing occurring even with the extended-release formulations. Laropiprant, a selective prostaglandin-2 receptor inhibitor, specifically targets the cascade of events causing the flushing. It has been recently used in combination with extended-release niacin. This article will review the early experience with this combination with focus on efficacy, safety, tolerability and current place in therapy. Early data are promising and suggest that more patients in clinical practice will benefit from niacin combined with laropiprant. Ongoing clinical trials will provide a better insight on the long-term safety of the drug and its efficacy for reducing cardiovascular events.
Keywords: niacin, laropiprant, dyslipidemias, hypercholesterolemia
Readers of this article also read:
Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect
Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures
Critical appraisal and clinical utility of atosiban in the management of preterm labor
Succession planning for advanced nursing practice; contingency or continuity? The Scottish experience
Baseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherence
The emerging role of nimotuzumab in the treatment of non-small cell lung cancer
The influence of locus control on adherence to treatment regimen among hypertensive patients
Differences in taste between three polyethylene glycol preparations: a randomized double-blind study
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- American Acne and Rosacea Society
The American Acne and Rosacea Society (AARS), is a 501(c)(6) non-profit organization dedicated to elevating the understanding and treatment of acne and rosacea.
- The benefits and risks of testosterone replacement therapy: a review
- Tenofovir-associated bone density loss
- Drug design with Cdc7 kinase: a potential novel cancer therapy target
- Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses




